Publicacións nas que colabora con José Ramón González Juanatey (130)

2023

  1. Changes in circulating ApoJ-Glyc levels in patients with suspected acute coronary syndrome: The EDICA trial

    International Journal of Cardiology, Vol. 391

  2. Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World—MEMOGAL Study

    American Journal of Cardiovascular Drugs, Vol. 23, Núm. 5, pp. 583-593

  3. Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: The DAPA-MODA study

    European Journal of Heart Failure, Vol. 25, Núm. 8, pp. 1352-1360

  4. Trends in cardiovascular care in the National Health System in Spain. Data from the RECALCAR project 2011-2020

    Revista Espanola de Cardiologia, Vol. 76, Núm. 7, pp. 519-530

2022

  1. Differences Between Takotsubo and the Working Diagnosis of Myocardial Infarction With Nonobstructive Coronary Arteries

    Frontiers in Cardiovascular Medicine, Vol. 9

  2. Impact of the COVID-19 pandemic in the lipid control of the patients that start PCSK9 inhibitors

    Clinica e Investigacion en Arteriosclerosis, Vol. 34, Núm. 5, pp. 245-252

2021

  1. Evaluation of optimal medical therapy in acute myocardial infarction patients with prior stroke

    Therapeutic Advances in Chronic Disease, Vol. 12

  2. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

    Journal of the American College of Cardiology, Vol. 78, Núm. 5, pp. 421-433

  3. Prognostic Impact of Change in Nutritional Risk on Mortality and Heart Failure After Transcatheter Aortic Valve Replacement

    Circulation. Cardiovascular interventions, Vol. 14, Núm. 2, pp. e009342

2020

  1. Incidence, predictors and prognostic impact of intracranial bleeding within the first year after an acute coronary syndrome in patients treated with percutaneous coronary intervention

    European Heart Journal: Acute Cardiovascular Care, Vol. 9, Núm. 7, pp. 764-770

  2. P2Y12 inhibitors in acute coronary syndrome patients with renal dysfunction: an analysis from the RENAMI and BleeMACS projects

    European heart journal. Cardiovascular pharmacotherapy, Vol. 6, Núm. 1, pp. 31-42

  3. The impact of optimal medical therapy on patients with recurrent acute myocardial infarction: Subanalysis from the BleeMACS study

    International Journal of Cardiology, Vol. 318, pp. 1-6

2019

  1. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

    The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 8, pp. 618-628

  2. Impact of Coronary Revascularization in Patients Who Underwent Transcatheter Aortic Valve Implantation

    American Journal of Cardiology, Vol. 123, Núm. 6, pp. 948-955

  3. Long-Term Weight Gain Associated With High Omentin Levels at Hospital Discharge Improves Prognosis of Patients Following Acute Heart Failure

    Journal of Cardiovascular Translational Research, Vol. 12, Núm. 3, pp. 231-239

  4. Nutritional risk index predicts survival in patients undergoing transcatheter aortic valve replacement

    International Journal of Cardiology, Vol. 276, pp. 66-71

  5. Transcatheter Aortic Valve Replacement in Patients With Morbid Obesity: Procedure Outcomes and Medium-Term Follow-Up

    JACC: Cardiovascular Interventions

2018

  1. Alirocumab and cardiovascular outcomes after acute coronary syndrome

    New England Journal of Medicine, Vol. 379, Núm. 22, pp. 2097-2107

  2. Association of Beta-Blockers with Survival on Patients Presenting with ACS Treated with PCI: A Propensity Score Analysis from the BleeMACS Registry

    American Journal of Cardiovascular Drugs, Vol. 18, Núm. 4, pp. 299-309

  3. Development and external validation of a post-discharge bleeding risk score in patients with acute coronary syndrome: The BleeMACS score

    International Journal of Cardiology, Vol. 254, pp. 10-15